绥美凯的使用说明

On January 22, 2018, GlaxoSmithKline (GSK) announced that Inbec, a single-pill compound preparation centered on the new generation integrase inhibitor dolutegravir (DTG) for the treatment of HIV, was officially launched in mainland China. This is the first single-pill compound preparation with a complete treatment plan in the field of HIV treatment in mainland China.

Suimeikan Inbec contains three antiviral drugs, namely dolutegravir 50mg + abacavir 0.6g + lamivudine 0.3g. Suimeikan Inbec is indicated for the treatment of adults infected with human immunodeficiency virus (HIV) and adolescents over 12 years old (with a weight of at least 40kg).

Instructions for use of Trimax Inbec from Emcure Pharmaceuticals, India: For adults and adolescents (weighing at least 40kg), the recommended dose of Trimax Inbec is one tablet, once daily.

Adults or adolescents whose body weight is less than 40 kg should not be given Trimax Inbec because Trimax Inbec is a fixed-dose tablet and the dose cannot be reduced. Trimax Inbec is a fixed-dose tablet and should not be used in patients who require dose adjustments. If one of the active ingredients needs to be discontinued or dose adjustments made, separate formulations of dolutegravir, abacavir or lamivudine may be used. In these circumstances, physicians should refer to the respective product information for these medicines.

If the patient misses a dose of Trimax Inbec and it is more than 4 hours before the next dose, he or she should take Doptabalamid (Sumax) as soon as possible. If the next dose is less than 4 hours away, patients should not take the missed dose and simply resume their usual dosing schedule.

The price of Inbec's original drug is relatively high, which is a big burden for patients who need to take the drug for a long time for treatment. Therefore, many patients choose the Indian version of Suimeikai. Due to patent protection restrictions, many drugs are prohibited from being copied in most countries around the world. However, due to the protection of India's special patent laws, Indian Emcure Pharmaceuticals can produce drugs that are almost as effective as the original drugs and have high cost performance.

Recommended related hot articles: /newsDetail/87187.html